CLDN23 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| IHC-P, WB, E |
---|---|
Primary Accession | Q96B33 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 31915 Da |
Antigen Region | 228-257 aa |
Gene ID | 137075 |
---|---|
Other Names | Claudin-23, CLDN23 |
Target/Specificity | This CLDN23 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 228-257 amino acids from the C-terminal region of human CLDN23. |
Dilution | WB~~1:1000 IHC-P~~1:50~100 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | CLDN23 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | CLDN23 |
---|---|
Function | Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. |
Cellular Location | Cell junction, tight junction. Cell membrane; Multi-pass membrane protein |
Tissue Location | Expressed in germinal center B-cells, placenta, stomach as well as in colon tumor. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CLDN23 is a four-transmembrane protein with WWCC motif, defined by W-X(17-22)-W-X(2)-C-X(8-10)-C. It is a candidate tumor suppressor gene implicated in intestinal-type gastric cancer.
References
Rikova, K., et al. Cell 131(6):1190-1203(2007)
Ballana, E., et al. BMC Med. Genet. 8, 81 (2007) :
Katoh, M., et al. Int. J. Mol. Med. 11(6):683-689(2003)
Venter, J.C., et al. Science 291(5507):1304-1351(2001)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.